UCB (EBR:UCB) UCB Media Room – Acquisition of own shares
Directive transparence : information réglementée Communiqué sur comptes, résultats, chiffres d’affaires
24/03/2023 20:00
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
** Acquisition of own shares
------------------------------------------------------------
Brussels (Belgium), 24 March 2023 =E2=80=93 20:00 (CET) =E2=80=93 Regulated=
information
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB=C2=A0SA/NV (=E2=80=
=9CUCB=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby di=
scloses certain information in relation to its Share Repurchase Program 202=
3.
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 500 000 UCB shares on its behalf under the terms of a discretionary=
mandate agreement with initial validity until 28 April 2023, effective as =
from 27 February 2023, to cover current and future obligations under UCB's =
Long Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2023, UCB repurchased 57.=
644 UCB shares on Euronext Brussels on 17 March 2023, as follows:
https://mb.cision.com/Public/18595/3740525/8955cf0016593faa_800x800ar.png
=E2=80=8BAs a result thereof, the Share Repurchase Program 2023 has been co=
mpleted.
This press release is available on UCB=C2=A0SA/NV=E2=80=99s website via the=
following link. (https://www.ucb.com/stories-media/Press-Releases)
For further information, contact UCB:
Investor Relations
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com (mailto:antje.witte@ucb.com)
Corporate Communications
Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com (mailto:laurent.schots@ucb.com) =C2=A0=C2=A0=C2=A0=
=C2=A0=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 700 peopl=
e in 36 countries, the company generated revenue of =E2=82=AC 5.5 billion i=
n 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
GenericFile
230324 - Verwerving van eigen aandelen NL (https://mb.cision.com/Public/185=
95/3740525/8bd7946cce31cb85.docx) GenericFile
230324 - Rachat d actions propres FR (https://mb.cision.com/Public/18595/37=
40525/a023a533cddde65e.docx) GenericFile
230324 - Acquisition of own shares ENG (https://mb.cision.com/Public/18595/=
3740525/a18cc6046a99738d.docx) Image
Schermafbeelding 2023-03-24 om 16 54 50 (https://mb.cision.com/Public/18595=
/3740525/8955cf0016593faa_org.png)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x132132x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01